NuGen Medical Devices Inc.
NGMDF
$0.02
$0.008.90%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -79.66% | -93.54% | 46.79% | 131.25% | 139.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -79.66% | -93.54% | 46.79% | 131.25% | 139.52% |
| Cost of Revenue | -73.22% | -95.06% | 52.38% | 133.33% | 73.41% |
| Gross Profit | -85.13% | -92.02% | 43.28% | 130.77% | 254.75% |
| SG&A Expenses | 10.26% | -46.23% | 59.54% | -47.56% | -56.85% |
| Depreciation & Amortization | 26.99% | -- | 1.37% | -14.08% | 0.71% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.07% | -54.32% | 45.93% | -41.30% | -47.25% |
| Operating Income | -38.06% | 44.53% | -45.91% | 46.83% | 61.60% |
| Income Before Tax | -1,121.18% | 37.15% | -141.63% | 180.73% | 119.31% |
| Income Tax Expenses | 1,342.86% | -141.77% | -- | -- | -114.97% |
| Earnings from Continuing Operations | -1,122.88% | 37.52% | -142.06% | 180.53% | 119.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,122.88% | 37.52% | -142.06% | 180.53% | 119.26% |
| EBIT | -38.06% | 44.53% | -45.91% | 46.83% | 61.60% |
| EBITDA | -44.44% | 48.67% | -59.83% | 51.84% | 68.39% |
| EPS Basic | -1,064.71% | 40.00% | -131.25% | 172.73% | 117.89% |
| Normalized Basic EPS | -291.30% | 40.32% | -119.05% | 173.17% | 61.02% |
| EPS Diluted | -1,064.71% | 40.00% | -131.25% | 172.73% | 117.89% |
| Normalized Diluted EPS | -291.30% | 40.32% | -119.05% | 173.17% | 61.02% |
| Average Basic Shares Outstanding | 3.45% | 4.47% | 5.17% | 10.48% | 10.21% |
| Average Diluted Shares Outstanding | 3.45% | 4.47% | 5.17% | 10.48% | 10.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |